Intensive Care Unit, Shengjing Hospital of China Medical University, Liaoning, China.
Interventional Ward, Shengjing Hospital of China Medical University, Liaoning, China.
Medicine (Baltimore). 2022 Nov 25;101(47):e31699. doi: 10.1097/MD.0000000000031699.
Dyspnea is a hallmark symptom of heart failure. The existing clinical studies have indicated that opioid can effectively improve the clinical symptoms of heart failure patients with dyspnea. However, there has not been any relevant systematic review and meta-analysis. We performed a protocol for systematic review and meta-analysis to evaluate the safety and efficacy of opioid therapy for heart failure patients with refractory dyspnea.
We searched 3 foreign electronic databases (Cochrane Library, Embase, Pubmed) and 4 Chinese electronic databases (China National Knowledge Infrastructure, Wang Fang Database, Chinese Biomedical Literature Database and Chinese Scientific Journal Database) to collect potential studies from their inceptions to October 2022. The risk of bias in the included articles was assessed according to the Risk of Bias Assessment Tool in Cochrane Handbook of Systematic Reviews (5th edition). The quality of evidence was assessed by the Grading of Recommendations Assessment, Development and Evaluation approach. Data were analyzed using the RevMan Version 5.4.1.
This study will evaluate whether opioid is effective and safe for treating refractory dyspnea in patients with heart failure.
This meta-analysis will provide comprehensive evidence of opioid therapy for heart failure patients with dyspnea.
呼吸困难是心力衰竭的标志性症状。现有临床研究表明，阿片类药物能有效改善呼吸困难的心力衰竭患者的临床症状。然而，目前尚无相关的系统评价和荟萃分析。我们制定了系统评价和荟萃分析方案，以评估阿片类药物治疗难治性呼吸困难心力衰竭患者的安全性和疗效。
我们检索了 3 个外文电子数据库（Cochrane 图书馆、Embase、Pubmed）和 4 个中文电子数据库（中国知网、万方数据库、中国生物医学文献数据库和中国科学引文数据库），从建库至 2022 年 10 月，收集潜在的研究。根据 Cochrane 系统评价手册（第 5 版）的偏倚风险评估工具评估纳入文章的偏倚风险。采用推荐评估、制定与评价分级法评估证据质量。使用 RevMan Version 5.4.1 进行数据分析。
本研究将评估阿片类药物治疗心力衰竭伴难治性呼吸困难患者是否有效和安全。
这项荟萃分析将为呼吸困难心力衰竭患者的阿片类药物治疗提供全面的证据。
